DZ3318A1 - Inhibiteur de proteinase - Google Patents

Inhibiteur de proteinase

Info

Publication number
DZ3318A1
DZ3318A1 DZ013318A DZ013318A DZ3318A1 DZ 3318 A1 DZ3318 A1 DZ 3318A1 DZ 013318 A DZ013318 A DZ 013318A DZ 013318 A DZ013318 A DZ 013318A DZ 3318 A1 DZ3318 A1 DZ 3318A1
Authority
DZ
Algeria
Prior art keywords
proteinase inhibitor
proteinase
inhibitor
Prior art date
Application number
DZ013318A
Other languages
English (en)
French (fr)
Inventor
Robert Wells Marquis Jr
Daniel Frank Veber
Yu Ru
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ3318A1 publication Critical patent/DZ3318A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/14—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ013318A 2000-03-21 2001-03-07 Inhibiteur de proteinase DZ3318A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US19100000P 2000-03-21 2000-03-21
US20634100P 2000-05-23 2000-05-23
US21175900P 2000-06-14 2000-06-14
US21744500P 2000-07-10 2000-07-10
US10/239,343 US7071184B2 (en) 2000-03-21 2001-03-07 Protease inhibitors
PCT/US2001/007094 WO2001070232A1 (en) 2000-03-21 2001-03-07 Protease inhibitors
US11/410,558 US7563784B2 (en) 2000-03-21 2006-04-25 Protease inhibitors

Publications (1)

Publication Number Publication Date
DZ3318A1 true DZ3318A1 (fr) 2001-09-27

Family

ID=27497873

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013318A DZ3318A1 (fr) 2000-03-21 2001-03-07 Inhibiteur de proteinase

Country Status (26)

Country Link
US (2) US7071184B2 (enExample)
EP (1) EP1307203A4 (enExample)
JP (1) JP2003527429A (enExample)
KR (1) KR20020082896A (enExample)
CN (1) CN1416346A (enExample)
AP (1) AP1540A (enExample)
AR (1) AR032877A1 (enExample)
AU (2) AU4344101A (enExample)
BG (1) BG106962A (enExample)
BR (1) BR0109356A (enExample)
CA (1) CA2404206A1 (enExample)
CZ (1) CZ20023168A3 (enExample)
DZ (1) DZ3318A1 (enExample)
EA (1) EA005893B1 (enExample)
HU (1) HUP0300068A2 (enExample)
IL (1) IL150964A0 (enExample)
MX (1) MXPA02009305A (enExample)
MY (1) MY141596A (enExample)
NO (1) NO20024528L (enExample)
NZ (1) NZ520588A (enExample)
OA (1) OA12323A (enExample)
PE (1) PE20011233A1 (enExample)
PL (1) PL357727A1 (enExample)
SK (1) SK13632002A3 (enExample)
UY (1) UY26625A1 (enExample)
WO (1) WO2001070232A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
CZ20023168A3 (cs) * 2000-03-21 2003-02-12 Smithkline Beecham Corporation Inhibitory proteázy
CO5280088A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Inhibidores de proteasa
CO5280093A1 (es) * 2000-04-18 2003-05-30 Smithkline Beecham Corp Metodos de tratamiento
JP2004509083A (ja) * 2000-09-01 2004-03-25 スミスクライン・ビーチャム・コーポレイション 治療方法
WO2003053331A2 (en) * 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
WO2003045909A2 (en) * 2001-11-21 2003-06-05 Smithkline Beecham Corporation Methods and intermediates for the synthesis of azepines
WO2003097593A2 (en) * 2002-05-22 2003-11-27 Smithkline Beecham Corporation Protease inhibitors
US20060166966A1 (en) * 2002-10-08 2006-07-27 Cameron Black 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US20040192674A1 (en) * 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
WO2005069981A2 (en) * 2004-01-23 2005-08-04 Smithkline Beecham Corporation Method of preparation of benzofuran-2-carboxylic acid {(s)-3-methyl-1-[(4s, 7r)-7methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide
KR100603014B1 (ko) * 2004-07-21 2006-07-24 황호연 라벨용 포장필름의 제조방법, 상기 제조방법으로 제조된라벨용 포장필름 및 상기 포장필름의 사용방법
MX2007003858A (es) * 2004-10-07 2007-12-11 Vitae Pharmaceuticals Inc Diaminoalcanos inhibidores de proteasa asparticas.
PE20070171A1 (es) * 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
TWI411607B (zh) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
CL2007002689A1 (es) * 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2168600A1 (en) 2007-06-08 2010-03-31 Nippon Chemiphar Co., Ltd. Therapeutic or prophylactic agent for cerebral aneurysm
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
EP2167609A1 (en) * 2007-06-20 2010-03-31 Vitae Pharmaceuticals, Inc. Renin inhibitors
EP2216047A4 (en) 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
JP2011525488A (ja) * 2008-06-20 2011-09-22 ヴァイティー ファーマシューティカルズ，インコーポレイテッド レニン阻害剤およびその使用方法
CA2729052A1 (en) * 2008-06-26 2009-12-30 Vitae Pharmaceuticals, Inc. Salts of methyl 2-((r)-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate
AR077692A1 (es) * 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
MX2013013281A (es) 2011-05-16 2013-12-06 Bayer Ip Gmbh Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
CN103275070A (zh) * 2013-05-10 2013-09-04 郑彪 调节单核细胞增殖的四环化合物及其应用
US9481707B2 (en) * 2013-06-14 2016-11-01 Seikagaku Corporation α-oxoacyl amino-caprolactam derivative
JP6226437B2 (ja) * 2013-06-14 2017-11-08 生化学工業株式会社 α−オキソアシルアミノカプロラクタム体
CN109983012B (zh) 2016-09-16 2023-12-01 莱特豪斯制药公司 赖氨酸牙龈蛋白酶的酮抑制剂
WO2021191875A1 (en) 2020-03-26 2021-09-30 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038247A (en) 1970-05-19 1977-07-26 Ciba-Geigy Corporation Stabilizing polyolefins with diacyl dihydrazides
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
IT1195287B (it) 1981-11-05 1988-10-12 Ausonia Farma Srl Derivato tiazolico,procedimento per la sua preparazione e relative composizioni farmaceutiche
ZA829141B (en) 1981-12-14 1983-09-28 Merck & Co Inc Process for reducing lactams
ZA839532B (en) 1982-12-27 1985-08-28 Merck & Co Inc Lactams and bicyclic lactams as antihypertensive agents
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US4749792A (en) 1984-09-26 1988-06-07 E. R. Squibb & Sons, Inc. Diamino ketones and alcohols as analgesic agents
US4638101A (en) 1985-01-02 1987-01-20 General Electric Company Compositions
US4638010A (en) * 1985-02-28 1987-01-20 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
HU201032B (en) 1986-03-14 1990-09-28 Syntex Inc Process for production of izoxasoles hindering transglumatinase and medical compositions containing them
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
US5374637A (en) 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4994471A (en) 1989-05-12 1991-02-19 Boc, Inc. N-aryl-N-(1-substituted-3-alkoxy-4-piperidinyl)amides and pharmaceutical compositions and methods employing such compounds
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
EP0504938A3 (en) 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
JPH05140063A (ja) 1991-11-19 1993-06-08 Suntory Ltd ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤
US5206251A (en) 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5216168A (en) 1992-04-01 1993-06-01 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
JPH09500087A (ja) 1992-06-24 1997-01-07 コーテックス ファーマシューティカルズ インコーポレイテッド カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法
US5374623A (en) 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
EP0603769B1 (en) 1992-12-25 1998-09-16 Mitsubishi Chemical Corporation Alpha-Aminoketone derivatives
CA2111930A1 (en) 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
JPH06199850A (ja) 1992-12-28 1994-07-19 Tanabe Seiyaku Co Ltd インドール含有ペプチド及びその製法
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
EP1645629A1 (en) 1993-04-06 2006-04-12 Forsyth Dental Infirmary For Children Human osteoclast-specific and related genes
TW494094B (en) 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5866545A (en) 1993-08-13 1999-02-02 Merck & Co., Inc. Substituted ketone derivatives as inhibitors of interleukin-1β converting enzyme
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
DE69510338T2 (de) 1994-04-13 1999-10-14 Takeda Chemical Industries Azirdin-derivate, deren herstellung und verwendung
US5585387A (en) 1994-10-07 1996-12-17 Torcan Chemical Ltd. Prepration of cisapride
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5734977A (en) * 1994-11-10 1998-03-31 Telefonaktiebolaget Lm Ericsson Fraud detection in radio communications network
TW438591B (en) 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
EA199700087A1 (ru) 1995-10-30 1998-04-30 Смитклайн Бичам Корпорейшн Способ ингибирования катепсина к
TR199800767T2 (xx) 1995-10-30 1998-07-21 Smithkline Beecham Corporation Proteaz engelleyicileri.
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US5902882A (en) 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
WO1997049668A1 (en) 1996-06-13 1997-12-31 Smithkline Beecham Corporation Inhibitiors of cysteine protease
WO1997047642A1 (en) 1996-06-14 1997-12-18 Smithkline Beecham Corporation Cathepsin k gene
US5861298A (en) 1996-06-17 1999-01-19 Smithkline Beecham Corporation Cathepsin K gene
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
US5830850A (en) 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
WO1998008802A1 (en) 1996-08-28 1998-03-05 Smithkline Beecham Corporation Inhibitors of cysteine protease
WO1998012211A1 (en) 1996-09-19 1998-03-26 Hoechst Marion Roussel, Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
US5948669A (en) 1997-02-26 1999-09-07 Smithkline Beecham Corporation Rat cathepsin K polynucleotide and polypeptide sequence
AR012374A1 (es) 1997-04-15 2000-10-18 Smithkline Beecham Corp Inhibidores de proteasas, composiones farmaceuticas y usos para la preparacion de medicamentos.
WO1998049152A1 (en) 1997-04-25 1998-11-05 Smithkline Beecham Corporation Protease inhibitors
MA26487A1 (fr) 1997-04-29 2004-12-20 Smithkline Beecham Corp Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
US6566373B2 (en) 1997-05-06 2003-05-20 Smithkline Beecham Corporation Protease inhibitors
CA2289602A1 (en) 1997-05-08 1998-11-12 William Edward Bondinell Protease inhibitors
BR9808502A (pt) 1997-05-08 2000-05-23 Smithkline Beecham Corp Inibidores de protease
MA26540A1 (fr) 1997-09-04 2004-12-20 Smithkline Beecham Corp Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant.
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
DZ2796A1 (fr) 1998-05-21 2003-12-01 Smithkline Beecham Corp Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
WO1999059570A1 (en) 1998-05-21 1999-11-25 Smithkline Beecham Corporation Protease inhibitors
DZ2815A1 (fr) 1998-06-12 2003-12-01 Smithkline Beecham Corp Inhibiteurs de protéase.
AR018915A1 (es) 1998-06-24 2001-12-12 Smithkline Beecham Corp Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
JP2003527819A (ja) 1998-08-14 2003-09-24 スミスクライン・ビーチャム・コーポレイション カテプシンｋの阻害方法
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
CO5180541A1 (es) 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
IL143142A0 (en) 1998-12-23 2002-04-21 Smithkline Beecham Corp Protease inhibitors
US20030044399A1 (en) 1998-12-23 2003-03-06 Smithkline Beecham Corporation Method of treatment
AU756174B2 (en) * 1999-02-09 2003-01-09 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
DZ3083A1 (fr) 1999-02-19 2004-06-02 Smithkline Beecham Corp Composés nouveaux inhibiteurs de protéases, procédé pour leur préparation et compositions pharmaceutiques les conentant.
UY26026A1 (es) 1999-03-16 2000-10-31 Smithkline Beecham Corportion Inhibidores de proteasas
UY26088A1 (es) 1999-03-31 2000-10-31 Smithkline Beecham Corp Inhibidores de proteasas
HUP0203375A3 (en) 1999-07-28 2005-03-29 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl compounds
JP2003533432A (ja) 1999-11-10 2003-11-11 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
EP1235577A4 (en) 1999-11-10 2003-04-09 Smithkline Beecham Corp PROTEASE INHIBITORS
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
EP1231921A4 (en) 1999-11-10 2004-06-23 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034155A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
JP2003513928A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
EP1229912A4 (en) 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
JP2003513927A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテア−ゼ阻害剤
EP1229911A4 (en) 1999-11-10 2003-05-07 Smithkline Beecham Corp PROTEASE INHIBITORS
WO2001034157A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
DE10004572A1 (de) * 2000-02-02 2001-08-09 Boehringer Ingelheim Pharma Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CZ20023168A3 (cs) * 2000-03-21 2003-02-12 Smithkline Beecham Corporation Inhibitory proteázy
US20030114437A1 (en) 2002-10-17 2003-06-19 Cummings Maxwell D. Protease inhibitors
JP2004509083A (ja) 2000-09-01 2004-03-25 スミスクライン・ビーチャム・コーポレイション 治療方法
WO2003053331A2 (en) 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
US20040034013A1 (en) 2001-04-17 2004-02-19 Cummings Maxwell D Methods of treatment
WO2002092563A2 (en) 2001-05-17 2002-11-21 Smithkline Beecham Corporation Protease inhibitors
WO2003026770A1 (en) 2001-09-24 2003-04-03 Smithkline Beecham Corporation Method for removing metal from the products of olefin metathesis reactions
WO2003045909A2 (en) 2001-11-21 2003-06-05 Smithkline Beecham Corporation Methods and intermediates for the synthesis of azepines
EP1534292A4 (en) 2002-05-22 2008-04-02 Smithkline Beecham Corp PROTEASE INHIBITORS
US20050203084A1 (en) 2002-05-22 2005-09-15 Jeong Jae U. Protease inhibitors
WO2003097593A2 (en) 2002-05-22 2003-11-27 Smithkline Beecham Corporation Protease inhibitors
AU2003269878A1 (en) 2002-05-22 2003-12-22 Smithkline Beecham Corporation Protease inhibitors
EP1511492A2 (en) 2002-05-22 2005-03-09 Smithkline Beecham Corporation Protease inhibitors
US20050030912A1 (en) 2002-08-22 2005-02-10 Enikia L.L.C. Use of hybrid (HW/DSP/MCU/SW) architectures for powerline OFDM communication field
WO2005013909A2 (en) 2003-08-07 2005-02-17 Smithkline Beecham Corporation Novel cathepsin k inhibitors
US7366462B2 (en) 2003-10-24 2008-04-29 Qualcomm Incorporated Method and apparatus for seamlessly switching reception between multimedia streams in a wireless communication system

Also Published As

Publication number Publication date
AU2001243441B2 (en) 2004-11-25
CN1416346A (zh) 2003-05-07
HUP0300068A2 (en) 2003-05-28
KR20020082896A (ko) 2002-10-31
IL150964A0 (en) 2003-02-12
EP1307203A4 (en) 2005-08-17
WO2001070232A1 (en) 2001-09-27
US7563784B2 (en) 2009-07-21
AP2002002593A0 (en) 2002-09-30
PL357727A1 (en) 2004-07-26
UY26625A1 (es) 2001-09-28
CA2404206A1 (en) 2001-09-27
MY141596A (en) 2010-05-31
NO20024528L (no) 2002-11-19
BR0109356A (pt) 2003-06-03
NO20024528D0 (no) 2002-09-20
EA005893B1 (ru) 2005-06-30
CZ20023168A3 (cs) 2003-02-12
US20060194787A1 (en) 2006-08-31
US20040044201A1 (en) 2004-03-04
JP2003527429A (ja) 2003-09-16
MXPA02009305A (es) 2003-03-12
EP1307203A1 (en) 2003-05-07
BG106962A (bg) 2003-03-31
SK13632002A3 (sk) 2003-02-04
EA200201001A1 (ru) 2003-02-27
AU4344101A (en) 2001-10-03
AR032877A1 (es) 2003-12-03
OA12323A (en) 2006-05-15
AP1540A (en) 2006-01-11
US7071184B2 (en) 2006-07-04
NZ520588A (en) 2004-06-25
PE20011233A1 (es) 2002-02-07

Similar Documents

Publication Publication Date Title
DZ3318A1 (fr) Inhibiteur de proteinase
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
CY2015028I1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
DK1294714T3 (da) Trombinreceptorantagonister
IS6762A (is) Spíró-pýrimídín-2,4,6-tríón málmpróteinasa hindrar
DE60126142D1 (de) Bioabsorbierbare wundauflage
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE60131340D1 (de) Schallabsorbtionsstruktur
DZ3409A1 (fr) Association therapeuthique
IS6599A (is) 2-amínókarbónýl-9H-púrínafleiður
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
NO20025786L (no) Protaseinhibitorer
PT1339695E (pt) Inibidores da farnesiltransferase
AR027931A1 (es) Antitranspirantes
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
NO20025005D0 (no) Proteaseinhibitorer
AR028075A1 (es) Inhibidores de la peptido-desformilasa
DE60132468D1 (de) Alen-lanosterol zyklase inhibitoren
NO20032328L (no) Proteaseinhibitorer
ATE284887T1 (de) Thienopyrrolidinone